Evolus Inc buy klostergang
Start price
19.03.19
/
50%
€21.91
Target price
22.04.20
€31.57
Performance (%)
-81.38%
End price
22.04.20
€4.08
Summary
This prediction ended on 22.04.20 with a price of €4.08. Massive losses of -81.38% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evolus Inc | -5.882% | -5.882% | 43.590% | 18.519% |
| iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
| iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
| iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
| iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
Comments by klostergang for this prediction
In the thread Evolus Inc diskutieren
Evolus obtained FDA approval for its product Jeuveau to treat patients with glabellar lines.
FDA approval was given to Jeuveau on the basis of the TRANSPARENCY program that treated over 2,100 patients with successful results.
Allergan has a competing product in the aesthetic market, known as Botox, which generated $3.58 billion in revenue in 2018 alone.
Es gibt keinen Handelsplatz